News

A signaling protein (Smad7) that usually blocks the activity of a molecule called transforming growth factor-beta (TGF-β) appears to be overactive in people with multiple sclerosis (MS), leading to the activation and migration of immune cells from the intestine to the central nervous system, a study reports. The study,…

The New York Stem Cell Foundation (NYSCF) Research Institute and Aspen Neuroscience will send three-dimensional brain cell models of primary progressive multiple sclerosis (PPMS) and Parkinson’s disease to the International Space Station (ISS) for the…

TD Bank Group has donated $1 million to the Multiple Sclerosis (MS) Society of Canada to support research projects aiming to use artificial intelligence to create tools enabling better use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients. MS Society will channel these funds into its Acts of Greatness campaign,…

When Jon Strum began his “RealTalk MS” podcast two years ago, he did not imagine he soon would have thousands of regular listeners in more than 60 countries. Now, Strum’s popular online audio series has a new partner: the National Multiple Sclerosis Society (NMSS). Strum uses his weekly…

NeurologyLive, a platform for healthcare specialists, has added The Consortium of Multiple Sclerosis Centers (CMSC) to its Strategic Alliance Partnership program that works to share insights and experiences to benefit people with multiple sclerosis (MS) and their families. A collaborative mix of neurological centers, networks, and…

A small RNA molecule found in high levels in the gut of people with multiple sclerosis (MS) could be used to develop a new therapy for MS in the future, an early research study reports. Orally giving this microRNA — called miR-30d — to mouse models of…

Researchers at the University of Michigan developed an online tool to help people with multiple sclerosis (MS) manage some of the more life-affecting symptoms of their disease. Called My MSToolkit, the tool is a free and web-based, self-guided program based on behavioral healthcare. It’s designed to help in managing…

Human herpesvirus 6A (HHV-6A), but not a widespread variant of the virus called HHV-6B, could be one of the root causes of multiple sclerosis (MS), new research suggests. Compared to healthy people, those with MS show greater numbers of antibodies to HHV-6A viruses, reflecting greater exposure to…

Mount Sinai Medical Center has joined with BrainStorm Cell Therapeutics to explore the safety and efficacy of NurOwn as a potential treatment for progressive multiple sclerosis (MS) in an ongoing Phase 2 trial. The New York center is the fourth clinical site participating in the trial, in addition…

Prices for new multiple sclerosis (MS) therapies in the United States are decided most by competitors’ prices, and continual increases in the cost of existing treatments by concerns for company profits and future growth, a study based on”confidential” interviews with four biotech executives with experience in the MS field reports. U.S.

GeNeuro is collaborating with clinical researchers at the Karolinska Institutet and the Academic Specialist Center (ASC) in Stockholm to open a new clinical trial of temelimab in people whose multiple sclerosis (MS) is progressing in the absence of relapses. Fredrik Piehl, MD, PhD, a professor of neurology at…

People with multiple sclerosis (MS) — both with and without cognitive impairments — have trouble processing sensory information, which is linked to greater disease severity and difficulties in daily life, a study reveals. The study is one of the first to look at the consequences of sensory processing deficits…

Vumerity (diroximel fumarate) carries fewer and less severe gastrointestinal side effects compared to Tecfidera (dimethyl fumarate), new data from a Phase 3 trial directly comparing the GI tolerability of these two relapsing-remitting multiple sclerosis (RRMS) treatments show. These results were presented at the 27th Annual Meeting of the European Charcot Foundation,…

A DNA analysis to identify changes in the gut microbiome in people newly diagnosed with multiple sclerosis — who have yet to begin using disease-modifying therapies — showed that all, regardless of ethnic background, have an abundance of the bacteria group Clostridia compared to people…

African-Americans and Hispanics with relapsing-remitting multiple sclerosis (RRMS) have higher blood levels of plasmablasts, a type of inflammatory immune cell that produces antibodies, than do Caucasians with this disease, a study found. The study “Black African and Latino/a identity correlates with increased plasmablasts in MS” was published in the journal…

Genentech‘s Ocrevus (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis (SPMS) among U.S. neurologists, even though Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) were approved in March to treat this same MS…

A blood-cleansing process known as immunoadsorption appears to be superior to plasma exchange in treating relapses that don’t respond to conventional steroid therapy in people with multiple sclerosis (MS) or clinically isolated syndrome (CIS), a study reports. These findings were reported in “Safety and efficacy of immunoadsorption…

There is a sizable gap between advancements in treatment for multiple sclerosis (MS) and their regulatory approval, which is a circumstance that necessitates increased  advocacy on a global scale. This concern was a major topic of conversation recently at the XXIV World Congress of Neurology (WCN 2019)…

MMJ International Holdings announced that it has entered into an agreement for the production of its proprietary cannabis-based gel capsule — a product mix of tetrahydrocannabinol (THC) and cannabidiol (CBD) — in compliance with guidelines set by the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).

Pregnancy does not lead to long-term changes in the disease course of multiple sclerosis (MS), new research suggests. This work, which emphasizes the importance of careful data analysis, supports studies disputing previous beliefs that pregnancy worsened or lessened the long-term disease course of MS. The findings were presented by Mar Tintore,…

Stopping the migration of immune B-cells through the blood-brain barrier by blocking ALCAM, a molecule linked to the progression of multiple sclerosis (MS), lessened disease severity in an MS mouse model, a new study shows. Details of the discovery were reported…

BrainStorm Cell Therapeutics received a $495,330 grant from the National Multiple Sclerosis (MS) Society  to support biomarker studies in its ongoing clinical trial testing the cell therapy NurOwn in patients with progressive multiple sclerosis (MS). NurOwn is a treatment based on the patients’ own bone marrow-derived mesenchymal stem…

A large retrospective study suggests that a magnetic resonance imaging (MRI) marker — called “brain atrophied T2 lesion volume” — could help predict the timing of multiple sclerosis (MS) progression. According to the study, this marker was the only MRI parameter capable of predicting disease progression, compared with other…

Novartis’s Mayzent (siponimod) has been approved by Australia’s Therapeutic Goods Administration (TGA) for the treatment of secondary progressive multiple sclerosis (SPMS), making it the first therapy to be approved for this use in Australia. SPMS is a form of MS that develops after the onset of…

The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…

Three academic research institutions launched the Weill Neurohub initiative, an effort to speed the discovery and development of therapies for neurological diseases that include multiple sclerosis (MS), Parkinson’s and Alzheimer’s disease, and for psychiatric disorders like anxiety, depression, and schizophrenia. The initiative unites three West Coast…

Depression and fatigue have a more powerful influence on the overall health-related quality of life, compared to physical impairment, among patients with multiple sclerosis, a new study shows. The study, “Contributing factors to health‐related quality of life in multiple sclerosis,” was published in the journal Brain and…

The National Multiple Sclerosis Society has criticized Biogen for the $88,000 yearly list price it placed on Vumerity (diroximel fumarate), the newly approved oral disease-modifying treatment (DMT) for relapsing multiple sclerosis. That criticism extends to repeated price increases with Tecfidera (dimethyl fumarate), Biogen’s similar oral DMT for…

With the help of 7 Tesla magnetic resonance imaging (MRI), investigators discovered that leptomeningeal enhancement — a radiographic finding indicative of brain inflammation — is more common than previously thought in people with relapsing-remitting multiple sclerosis (RRMS), and is tied to lesions in specific regions of the brain.

A single dose of CD45-ADC, an investigational targeted therapy being developed to treat different types of autoimmune diseases, is enough to reset the normal function of the body’s immune system in a mouse model of multiple sclerosis (MS), and to delay onset of the disease. Those findings…